Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 18/20 | 0.60 |
| ▸ | GAA | P10253 | 18/20 | 0.60 |
| ▸ | SI | P14410 | 18/20 | 0.60 |
| ▸ | MGAM2 | Q2M2H8 | 18/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6059111 | 0.89 | MGAM (0.53) | MGAMGAASIMGAM2 | |
| SCHEMBL7381090 | 0.86 | GAA (0.44) | MGAMGAASIMGAM2 | |
| SCHEMBL7381088 | 0.84 | MGAM (0.42) | MGAMGAASIMGAM2 | |
| SCHEMBL11498857 | 0.83 | MGAM (0.65) | MGAMGAASIMGAM2 | |
| Water SCHEMBL11498856 | 0.81 | MGAM (0.62) | MGAMGAASIMGAM2 | |
| SCHEMBL6702545 | 0.79 | MGAM (0.61) | MGAMGAASIMGAM2 | |
| SCHEMBL12549065 | 0.79 | ABL1 (0.62) | MGAMGAASIMGAM2 | |
| SCHEMBL12907800 | 0.78 | SLC6A4 (0.50) | — | |
| Ether SCHEMBL10542851 | 0.77 | MGAM (0.54) | MGAMGAASIMGAM2 | |
| SCHEMBL17754363 | 0.75 | MGAM (0.81) | MGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0877607-B1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | AVENTIS PHARMA SA (FR) | 2006-11-15 | — | — | EP | disclosed |
| US-6794415-B2 | Biphenyl compounds and their use as oestrogenic agents | AVENTIS PHARMA S.A. (FR) | 2004-09-21 | — | — | US | disclosed |
| US-20040043993-A1 | Biphenyl compounds and their use as oestrogenic agents | AVENTIS PHARMA S.A. | 2004-03-04 | — | — | US | disclosed |
| US-6563008-B2 | Treatment of disorders linked to hypofolliculinemia and of certain estrogen-dependent pathologies such as prostatic adenomas or carcinomas, and of benign tumours of the breast | AVENTIS PHARMA S.A. (FR) | 2003-05-13 | — | — | US | disclosed |
| US-20020068736-A1 | Biphenyl compounds and their use as oestrogenic agents | LESUISSE DOMINIQUE (FR) | 2002-06-06 | — | — | US | disclosed |
| US-6288126-B1 | Biphenyl compounds and use thereof as oestrogenic agents | AVENTIS PHARMA S.A. | 2001-09-11 | — | — | US | disclosed |
| EP-0877607-A1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | HOECHST MARION ROUSSEL (FR) | 1998-11-18 | — | — | EP | disclosed |
| WO-1997027846-A1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | HOECHST MARION ROUSSEL (FR) | 1997-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068736-A1 | Biphenyl compounds and their use as oestrogenic agents | ESR2, ESR1, CYP19A1 | MGAM 4441/4885GAA 3888/4885SI 3894/4885 |
| US-20040043993-A1 | Biphenyl compounds and their use as oestrogenic agents | CYP19A1, HSD17B11, GPER1 | MGAM 4752/4885GAA 3526/4885SI 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.